Form 4: Telesis Bio Inc. Director Sarah E. Hlavinka Reports Acquisition of Stock and Options

Director Sarah E. Hlavinka reports acquisition of Telesis Bio Inc. stock and options on July 24, 2024.

Summary

• On July 24, 2024, Sarah E. Hlavinka, a director of Telesis Bio Inc. (TBIO), reported acquiring 8,390 shares of common stock and options to purchase 5,268 shares.
• The 8,390 shares were acquired as restricted stock units (RSUs).
• 3,512 RSUs vest in equal annual installments, and 4,878 RSUs vest in full on January 1, 2025, contingent upon continued service.
• Options for 5,268 shares were acquired with an exercise price of $4.10, vesting in equal monthly installments over three years, also contingent upon continued service.
• Following the transaction, Hlavinka directly owns 8,390 shares of common stock and options for 5,268 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing reporting insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. They are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The acquisition of shares by a director may positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted stock units, TBIO, Telesis Bio Inc., Sarah E. Hlavinka, beneficial ownership